Endometrial histology during use of a low-dose estrogen-desogestrel oral contraceptive with a reduced hormone-free interval

Contraception

Volumn 60, Issue 3, 1999, Pages 151-154

  Archer, David F ^a  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

Author keywords

Desogestrel; Endometrial histology; Ethinyl estradiol; Oral contraceptive

Indexed keywords

DESOGESTREL PLUS ETHINYLESTRADIOL; ORAL CONTRACEPTIVE AGENT; PLACEBO; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SAFETY; ENDOMETRIUM BIOPSY; ENDOMETRIUM CYTOLOGY; ENDOMETRIUM HYPERPLASIA; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; METAPLASIA; ORAL CONTRACEPTION; ORAL DRUG ADMINISTRATION; SAMPLE;

EID: 0032779146     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0010-7824(99)00076-1     Document Type: Article

References (16)

1. Fotherby K., Caldwell A.D.S. New progestogens in oral contraception. Contraception. 49:1994;1-32.
2. Drife J. Benefits and risks of oral contraceptives. Adv Contracept. 6:(Suppl):1990;15-25.
3. Fotherby K., Caldwell A.D.S. Review the new low dose oral contraceptives . J Obstet Gynaecol. 14:1994;327-332.
4. Denis C. Contraception estroprogestative inconvénients de la diminution des estrogenes. Contracept Fertil Sex. 21:1993;481-488.
5. An open label multicenter non-comparative safety and efficacy study of the desogestrel containing oral contraceptive, MIRCETTE™ Am J Obstet Gynecol. 179:1998;S2-S8.
6. Coenen C.M., Hollanders J.M., Rolland R., Spielmann D., Bulten J. The effects of a low-dose gestodene-containing oral contraceptive on endometrial histology in healthy women. Eur J Contracept Reprod Health Care. 1:1996;325-329.
7. Ober W.B., Decker A., Clyman M.J., Roland M. Endometrial morphology after sequential medication with mestranol and chlormadinone. Obstet Gynecol. 28:1996;247-253.
8. Huggins G.R., Giuntoli R.L. Oral contraceptives and neoplasia. Fertil Steril. 32:1979;1-23.
9. Hulka B.S., Chambless L.E., Kaufman D.G., Fowler W.C. Jr, Greenberg B.G. Protection against endometrial carcinoma by combination-product oral contraceptives. JAMA. 247:1982;475-477.
10. Kaufman DW, Shapiro S, Slone D, et al. Decreased risk of endometrial cancer among oral-contraceptive users. N Engl J Med 1980;303:1045-7.
11. Rosenblatt K.A., Thomas D.B. Hormonal content of combined oral contraceptives in relation to the reduced risk of endometrial carcinoma. The WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Int J Cancer. 49:1991;870-874.
12. La Vecchia C., Franceschi S., Bruzzi P., Parazzini F., Boyle P. The relationship between oral contraceptive use, cancer and vascular disease. Drug Safety. 5:1990;436-446.
13. La Vecchia C., Tavani A., Franceschi S., Parazzini F. Oral contraceptives and cancer. A review of the evidence. Drug Safety. 14:1996;260-272.
14. Prentice R.L., Thomas D.B. On the epidemiology of oral contraceptives and disease. Adv Cancer Res. 49:1987;285-401.
15. Schlesselman J.J. Net effect of oral contraceptive use on the risk of cancer in women in the United States. Obstet Gynecol. 85:1995;793-801.
16. Rabe T., Nitsche D.C., Runnebaum B. The effects of monophasic and triphasic oral contraceptives on ovarian function and endometrial thickness. Eur J Contracept Reprod Health Care. 2:1997;39-51.